ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

2:15PM-2:30PM: Abstract Number: 0800

Microbiota-Derived Indole Promotes Collagen-Induced Arthritis Type-17 Immunity through Intestinal Dendritic Cell Cytokine Production

Abstracts: Rheumatoid Arthritis – Etiology and Pathogenesis (0795–0800)

2:15PM-2:30PM: Abstract Number: 0794

Using Artificial Intelligence to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models

Abstracts: Patient Outcomes, Preferences, & Attitudes (0789–0794)

3:00PM-3:15PM: Abstract Number: 0831

Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes II: Look What You Made Me Do (Prediction) (0831–0836)

3:00PM-3:15PM: Abstract Number: 0843

Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I (0843–0848)

3:00PM-3:15PM: Abstract Number: 0813

Impact of Tirzepatide on Musculoskeletal Pain and High-Risk Analgesic Use Among Non-Diabetic Patients with Overweight or Obesity: A Propensity Score-Matched, Active Comparator, New User Study

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia (0813–0818)

3:00PM-3:15PM: Abstract Number: 0825

Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules

Abstracts: Professional Education (0825–0830)

3:00PM-3:15PM: Abstract Number: 0837

Risk of New Proteinuria in Next Ten Years in SLE

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis (0837–0842)

3:00PM-3:15PM: Abstract Number: 0819

Subcellular resolution spatial transcriptomics reveals immune-stromal crosstalk within the synovium of patients with juvenile idiopathic arthritis

Abstracts: Pediatric Rheumatology – Basic Science (0819–0824)

3:15PM-3:30PM: Abstract Number: 0838

Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis (0837–0842)

3:15PM-3:30PM: Abstract Number: 0832

Elevated serum peptidylarginine deiminase 4 (PAD4) levels in anti-CCP antibody positive at-risk individuals with arthralgia who progress to rheumatoid arthritis.

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes II: Look What You Made Me Do (Prediction) (0831–0836)

3:15PM-3:30PM: Abstract Number: 0826

Impact of Large Language Models on Diagnostic Reasoning of Medical Students in Rheumatology: A Randomized Trial

Abstracts: Professional Education (0825–0830)

3:15PM-3:30PM: Abstract Number: 0844

Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I (0843–0848)

3:15PM-3:30PM: Abstract Number: 0820

Novel Autoantibodies Predictive of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus

Abstracts: Pediatric Rheumatology – Basic Science (0819–0824)

3:15PM-3:30PM: Abstract Number: 0814

Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia (0813–0818)

3:30PM-3:45PM: Abstract Number: 0821

Flipping The Switch – Classical Complement Activation closely linked to IFN-signalling in Stills Disease

Abstracts: Pediatric Rheumatology – Basic Science (0819–0824)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].